HeraMED Limited

HMD

AU0000028367

Advanced Medical Equipment & Technology

Market Closed - Australian S.E. Other stock markets 07:10:23 23/05/2024 BST			5-day change	1st Jan Change
0.015 ^AUD	+7.14%		-6.25%	-37.50%

05-20	HeraMED Appoints Auditor	MT
05-13	Transcript : HeraMED Limited - Special Call

HeraMED Limited Appoints David Groberman as Director

December 11, 2018 at 02:10 am

HeraMED Limited appointed David Groberman as Director, date of appointment is September 25, 2018.

Latest news about HeraMED Limited

HeraMED Appoints Auditor	05-20	MT
Transcript : HeraMED Limited - Special Call	05-13
HeraMED Obtains ASIC Approval for Extension to Hold 2024 Meeting	05-08	MT
HeraMED Partners With FemBridge for Maternity Health Service; Shares Jump 15%	03-13	MT
Heramed Limited Announces Board Changes	03-11	CI
HeraMED Limited Reports Earnings Results for the Full Year Ended December 31, 2023	02-29	CI
HeraMED Enters Strategic Collaboration with PHI Research	01-21	MT
HeraMED Limited Announces Emily Slade to Resign as Non-Executive Director	01-16	CI
HeraMED Enters Strategic Collaboration with GPEx	01-16	MT
HeraMED Signs Deal with US-based Wingwomen for Cardio Initiative in Pregnant Women	12-19	MT
HeraMED Concludes First Tranche of AU$1.25 Million Share Placement	12-15	MT
HeraMED Signs Partnership Agreement with Telstra Health; Shares Climb 4%	11-21	MT
HeraMED Launches Clinical Trial for Maternity Care Platform; Shares Surge 36%	11-08	MT
HeraMED CEO Steps Down; CFO Transitions to EVP Role; Shares Surge 33%	11-08	MT
HeraMED Limited Limited Announces Resignation of David Groberman as Chief Executive Officer with Immediate Effect	11-07	CI
HeraMED Limited Announces Resignation of David Groberman as Managing Director	11-07	CI
HeraMED Limited Reports Earnings Results for the Half Year Ended June 30, 2023	18/08/23	CI
Jianmin Pharmaceutical Group Co.,Ltd. completed the acquisition of 6.13% stake in HeraMED Limited from Hua Li Pharmaceutical Group Co.,Ltd.	24/07/23	CI
HeraMED Completes AU$2.58 Million Placement	13/07/23	MT
HeraMED Transitions Chair to Executive Role	03/07/23	MT
HeraMED's US Partner Signs Three-Year Commercial Deal with Caduceus Medical Group	15/06/23	MT
HeraMED Signs Enterprise Agreement with Fond for HeraCARE Platform; Shares Decline 4%	01/06/23	MT
Australian Shares Inch Down as Market Weighs Cooling, But Still High, US Inflation	11/05/23	MT
Heramed Signs Deal with Perth-based Private OB-GYN Group for HeraCARE Deployment; Shares Climb 10%	11/05/23	MT
Heramed Limited Announces Board Changes	20/04/23	CI

Hera Med Ltd is an Israel-based company that develops pregnancy monitoring solutions for home and professional use. It offers hardware solutions supported by software applications. Its product HeraBEAT, is a medical-grade, clinically-validated and connected Ultrasound Fetal Doppler device predominantly for use by an expectant mother to self-monitor her fetusâ heart rate (FHR) at home. HeraBEAT communicates with any smartphone (iOS/Android) through Bluetooth Low Energy (BLE). A mother can hold or strap the HeraBEAT device to her abdomen, and the collected data is transmitted to her smartphone where the relevant readings are displayed through an interface. The Company also develops a service model which includes a homecare pregnancy solution. In addition, the Company develops artificial intelligence (AI), machine-learning, computerized algorithms to monitor and analyze the data so a healthcare professional or home user is informed of the wellbeing of the fetus.

Sector

Advanced Medical Equipment & Technology

Calendar

30/05/2024 - Annual General Meeting

More about the company